Navigation

Multiple myeloma - lenalidomide

Lenalidomide for multiple myeloma in people who have received at least one prior therapy

Status: History
Expected date of issue: June 2009
Process: STA
Topic area:
  • Cancer
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Elangovan Gajraj
Communications manager: Alice Law
Project manager: Jeremy Powell
Assessment Group / Evidence Review Group: Peninsula Technology Assessment Group, University of Exeter (PenTAG)
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 27 June 2008
Final scope published: May 2008
1st appraisal committee meeting: 01 October 2008
2nd appraisal committee meeting 06 January 2009
3rd appraisal committee meeting: 03 March 2009
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers / Sponsors

  • Celgene (lenalidomide)

Patient / Carer Groups

  • Leukaemia CARE
  • Leukaemia Research Fund
  • Macmillan Cancer Support
  • Myeloma UK
  • Rarer Cancers Forum

Professional groups

  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians, Medical Oncology Joint Special Committee
  • Royal College of Radiologists
  • UK Myeloma Forum

Others

  • Department of Health
  • Rotherham PCT
  • Sandwell PCT
  • Welsh Assembly Government

General

  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturer(s)

  • Cephalon (doxorubicin) (CA&U not returned, not participating)
  • Celgene/Pharmion (thalidomide)
  • Genus Pharmaceuticals (vincristine) (CA&U not returned, not participating)
  • GlaxoSmithKline (melphalan)
  • Janssen-Cilag (bortezomib)
  • Mayne Pharma plc (doxorubicin, vincristine, dexamethasone) (declined to participate)
  • Medac (UK)(doxorubicin) (CA&U not returned, not participating)
  • Merck Sharp and Dohme (dexamethasone) (CA&U not returned, not participating)
  • Organon Laboratories (dexamethasone) (CA&U not returned, not participating)
  • Pfizer (cyclophosphamide, doxorubicin)
  • Rosemont Pharmaceuticals (dexamethasone) (CA&U not returned, not participating)
  • Schering - Plough (doxorubicin)
  • Teva UK (doxorubicin) (CA&U not returned, not participating)
  • Wockhardt UK (doxorubicin) (CA&U not returned, not participating)

Relevant research groups

  • MRC Clinical Trials Unit

Evidence Review Group

  • Peninsula Technology Assessment Group (PenTAG)
  • National Coordinating Centre for Health Technology Assessment

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

Top


 

Key documents

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.